3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma

      , ,

      JAMA Ophthalmology

      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e131">IMPORTANCE</h5> <p id="P2">There is growing evidence that statins may protect against the development or worsening of open-angle glaucoma (OAG). As researchers plan clinical trials to more definitively study whether statins indeed protect against OAG, it would be helpful to know whether specific daily dosages or types of statin confer a greater protective effect than others. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e136">OBJECTIVE</h5> <p id="P3">To assess whether the protective effect of statins on the risk of glaucoma varies depending on the daily dosage or type of statin taken. </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e141">DESIGN, SETTING, AND PARTICIPANTS</h5> <p id="P4">Using claims data from January 2001 to December 2009, we observed 25 420 patients with no preexisting glaucoma and quantified exposure to statins and other cholesterol-lowering medications. Using multivariable regression modeling, we assessed the hazard of developing OAG and how it varied by the daily dosage or type of statin and whether any protective effect persists after accounting for baseline low-density lipoprotein level. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e146">EXPOSURES</h5> <p id="P5">Different daily dosages and types of statins.</p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e151">MAIN OUTCOMES AND MEASURES</h5> <p id="P6">Hazard ratios (HRs) for developing OAG with 95% CIs.</p> </div><div class="section"> <a class="named-anchor" id="S6"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e156">RESULTS</h5> <p id="P7">Of the 25 420 patients who met the eligibility criteria for study inclusion, the mean (SD) age was 66.1 (5.8) years, and 14 112 (55.5%) were female. Additionally, 19 232 patients (84.1%) were white, 1252 (5.5%) were black, and 1558 (6.8%) were Latino. After accounting for baseline low-density lipoprotein levels, persons who filled prescriptions for statins continuously for 2 years had a 21% reduced risk of glaucoma compared with nonusers (adjusted HR, 0.79; 95% CI, 0.66–0.96; <i>P</i> = .02). There was no additional protective effect associated with taking the highest dosage of statins (80 mg) compared with a lower dosage (40 mg) (HR, 1.03; 95% CI, 0.59–1.80; <i>P</i> = .91). The protective effect of the following statins on OAG risk did not differ compared with atorvastatin, an inexpensive generic statin: lovastatin (HR, 1.09; 95% CI, 0.71–1.68; <i>P</i> = .69), cerivastatin (HR, 0.61; 95% CI, 0.09–4.41; <i>P</i> = .63), rosuvastatin (HR, 0.83; 95% CI, 0.48–1.44; <i>P</i> = .51), fluvastatin (HR, 0.89; 95% CI, 0.39–2.02; <i>P</i> = .78), pravastatin (HR, 1.29; 95% CI, 0.93–1.79; <i>P</i> = .13), and simvastatin (HR, 1.03; 95% CI, 0.83–1.29; <i>P</i> = .78). </p> </div><div class="section"> <a class="named-anchor" id="S7"> <!-- named anchor --> </a> <h5 class="section-title" id="d8449829e186">CONCLUSIONS AND RELEVANCE</h5> <p id="P8">Even after accounting for baseline low-density lipoprotein level, statin exposure continued to be associated with a reduction in OAG risk. Our study helps inform researchers of a reasonable daily dosage and type of statin to use when designing randomized clinical trials to assess the association between statin use and glaucoma. </p> </div>

          Related collections

          Author and article information

          Journal
          JAMA Ophthalmology
          JAMA Ophthalmol
          American Medical Association (AMA)
          2168-6165
          March 01 2017
          March 01 2017
          : 135
          : 3
          : 263
          Article
          10.1001/jamaophthalmol.2016.5406
          6126374
          28114645
          da290b83-23da-4989-bea4-140f8a270540
          © 2017

          Comments

          Comment on this article